Gimv

Gimv is a prominent European investment company headquartered in Antwerp that actively expands its Health and Care platform through specialized equity deployments. As a publicly listed firm with permanent capital characteristics, Gimv invests across multiple platforms, with the healthcare practice focused on medical devices, care delivery and tech-enabled services, and biotech opportunities. Their structure and Belgian and broader Benelux roots position them as a long-standing presence in European healthcare investing.

Gimv invests at Series B, Series C, and Growth stages, with checks of $5M to $25M per deployment, often leading or co-leading rounds and taking active board roles. Geographic focus spans Belgium, the Netherlands, France, Germany, and broader Europe, with selective cross-border activity into adjacent geographies. The firm’s permanent-capital structure gives it unusual flexibility on hold periods and follow-on commitments.

Founders should approach Gimv as a growth-stage partner expecting demonstrated commercial traction, defined unit economics, and a clear scaling plan rather than early-stage scientific risk. Expect institutional-quality diligence and structured value creation planning post-investment. Warm introductions through European growth-stage co-investors, bankers, or Gimv portfolio CEOs are the most effective entry path.